Grupo Antolin has posted 2019 sales down 4% to EUR5.2bn (US$5.6bn), while EBITDA increased to EUR435m from EUR356m.

“The results were achieved in a challenging market that continued to be affected by major uncertainties, such as Brexit, trade tensions and the fall of key markets, especially China,” said an Antolin statement.

“In light of the Covid-19 crisis, the company is adapting its strategy to this challenging new market situation. Grupo Antolin is currently concentrating all its efforts and resources dealing with the crisis and resuming production at its plants, applying the strictest health and safety protocols.

“To help in this crisis, the company has launched some solidarity initiatives manufacturing medical supplies that can be used by hospitals.”